Cellectis to Present Data on Genome Engineering for Adoptive Immunotherapy at the American Society of Clinical Oncology Annual Meeting
Published on May 14, 2015
New York, May 13, 2015 – Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that preclinical data on its gene-edited allogeneic CAR T-cells will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
The presentations include:
- UCART19, an Allogeneic “Off-the-Shelf” Adoptive T-Cell Immunotherapy Against CD19+ B-Cell Leukemias
Poster Session: Developmental Therapeutics—Immunotherapy
Presentation Time: Saturday, May 30, 2015, 8:00 - 11:30 a.m. Central
- Adoptive immunotherapy of acute myeloid leukemia (AML) with allogenic CAR T-cells targeting CD123.
Poster Session: Developmental Therapeutics—Immunotherapy
Presentation Time: Saturday, May 30, 2015, 8:00 - 11:30 a.m. Central
- A multidrug resistant engineered CAR T-cell for allogeneic combination immunotherapy.
Poster Session: Leukemia, Myelodysplasia, and Transplantation
Presentation Time: Sunday, May 31, 2015, 8:00 - 11:30 a.m. Central